Arginine-vasopressin and oxytocin response to cholecystokinin-tetrapeptide.
This study examined the effects of i.v. administration of cholecystokinin-tetrapeptide (CCK-4) on plasma release of arginine vasopressin (AVP) and oxytocin (OT) in women with premenstrual dysphoric disorder (PMDD) and control women, during both the follicular phase and the luteal phase of their menstrual cycle. Plasma AVP and OT concentrations increased following CCK-4 administration. AVP and OT response to CCK-4 was similar for PMDD and control women and unaffected by menstrual cycle phase. AVP and OT may play a role in the hypothalamo-pituitary adrenal (HPA) axis activity associated with the panic response induced by CCK-4.
Le Mellédo
J M
JM
Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada. jean-michel.lemelledo@ualberta.ca
Bradwejn
J
J
Koszycki
D
D
Bellavance
F
F
Bichet
D
D
D000328:Adult; D001127:Arginine Vasopressin / Q000494:pharmacology*; D002766:Cholecystokinin / Q000494:pharmacology*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D010121:Oxytocin / Q000096:biosynthesis*; D016584:Panic Disorder / Q000097:blood / Q000188:drug therapy; D010455:Peptides / Q000494:pharmacology*; D010919:Placebos; D011293:Premenstrual Syndrome / Q000097:blood / Q000188:drug therapy; D011863:Radioimmunoassay; D013758:Tetragastrin / Q000494:pharmacology; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
D010455:Peptides; D010919:Placebos; D014662:Vasoconstrictor Agents; D013758:Tetragastrin; D001127:Arginine Vasopressin; D010121:Oxytocin; D002766:Cholecystokinin